# Post Approval Observational Study to Learn More About How Safe Octocog Alfa is and How Well it Works in Patients With Severe Hemophilia A in India

> **NCT07446010** · — · NOT_YET_RECRUITING · sponsor: **Bayer** · enrollment: 33 (estimated)

## Conditions studied

- Severe Hemophilia A

## Interventions

- **DRUG:** Octocog alfa

## Key facts

- **NCT ID:** NCT07446010
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-29
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07446010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07446010, "Post Approval Observational Study to Learn More About How Safe Octocog Alfa is and How Well it Works in Patients With Severe Hemophilia A in India". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07446010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*